HPV Testing and Pap Test Market

Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens.

According to Latest Market research report Published by MarketsandMarkets the “HPV Testing and Pap Test Market Size, Share, Demand and Growth Analysis, forecast” the Global Market is expected to reach $ 4.52 billion, at a CAGR of 6.6%

key players operating in the Global HPV Testing and Pap Test Market;

Key players in the market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.)

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371

Major Dynamics Impacting the HPV Testing and Pap Test Market;

· Growth Drivers:

1. An increasing number of cervical cancer cases and a growing aging population

2. Increasing awareness of cervical cancer screening programs

3. Government initiatives and funding.

· Restraints

  1. Changes in regulatory guidelines for cervical cancer screening
  2. HPV vaccination

Objectives of The Study-

  • To analyze micro-markets with respect to individual growth trends, prospects, and contributions to the global HPV testing and Pap test market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players
  • To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Request Research Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371

Major Market Developments-

  • In April 2014, Roche received the U.S. FDA approval for its cobas HPV (Human Papillomavirus) Test, which is used as a first-line primary screening test for cervical cancer in women.
  • In February 2014, BD Diagnostics received the CE/IVD marking for the BD Onclarity HPV Assay that can be used on the new BD Viper LT System

Global HPV Testing and Pap Test Market Segmentation:

Based on the application, the Pap test market is segmented into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is expected to grow at the highest CAGR during the forecast period, owing to the growing incidences of cervical cancer.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.